TAVR Highlights: Self-expanding valves continue to impress | A new technique | Why implant depth matters | SAPT vs. DAPT

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.

Performing TAVR on a patient with bicuspid AS can be challenging. Transcatheter aortic root tricuspidization may represent a new treatment strategy for these patients, according to a new first-in-human trial.

TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.

The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 

Experts agree that most patients younger than 65 should be treated with surgery instead of TAVR. According to a new real-world analysis, however, more and more of these patients are undergoing TAVR.

Boston Scientific has invested heavily in Georgia-based MiRus, a rising name in the competitive TAVR landscape.

All-cause mortality after six months was significantly lower for patients discharged on SAPT. That trend remained in place after 24 months.

Researchers explored data from nearly 800 patients, focusing on a wide variety of outcomes.